Follicular thyroid cancer medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
* High doses of radioiodine is also used to treat microscopic bone metastasis | * High doses of radioiodine is also used to treat microscopic bone metastasis | ||
===Targeted Therapy=== | ===Targeted Therapy=== | ||
==== | * This type of treatment is done using:<ref name="pmid23185034">{{cite journal |vauthors=Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL |title=The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring |journal=J. Clin. Endocrinol. Metab. |volume=98 |issue=1 |pages=31–42 |date=January 2013 |pmid=23185034 |pmc=3537108 |doi=10.1210/jc.2012-2909 |url=}}</ref><ref name="pmid22007339">{{cite journal |vauthors=Cabanillas ME, Hu MI, Durand JB, Busaidy NL |title=Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer |journal=J Thyroid Res |volume=2011 |issue= |pages=985780 |date=2011 |pmid=22007339 |pmc=3189619 |doi=10.4061/2011/985780 |url=}}</ref> | ||
* Sorafenib | ** [[Sorafenib]], an Sorafenib is an orally active, multityrosine kinase inhibitor. | ||
* Lenvatinib | ** [[Lenvatinib]], an orally active, multitargeted tyrosine kinase inhibitor.<ref name="pmid25671254">{{cite journal |vauthors=Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI |title=Lenvatinib versus placebo in radioiodine-refractory thyroid cancer |journal=N. Engl. J. Med. |volume=372 |issue=7 |pages=621–30 |date=February 2015 |pmid=25671254 |doi=10.1056/NEJMoa1406470 |url=}}</ref> | ||
'''Adult''' | |||
* Preferred regimen: [[Lenvatinib]] 24 mg PO daily until disease progression or unacceptable [[toxicity]]. | |||
* Alternative regimen: [[Sorefenib]] 400 mg PO q12h until disease progression or unacceptable [[toxicity]]. | |||
* Alternative regimen: [[Larotrectinib]] 100 mg PO q12h until disease progression or unacceptable [[toxicity]]. | |||
* Alternative regimen: [[Entrectinib]] 600 mg PO daily until disease progression or unacceptable [[toxicity]]. | |||
===Radiation Therapy=== | ===Radiation Therapy=== | ||
* External radiation therapy is used for bone pain in bone metastasis. | * External radiation therapy is used for bone pain in bone metastasis. | ||
Revision as of 14:17, 27 September 2019
|
Follicular thyroid cancer Microchapters |
|
Differentiating Follicular thyroid cancer from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Follicular thyroid cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Follicular thyroid cancer medical therapy |
|
Risk calculators and risk factors for Follicular thyroid cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Pharmacologic medical therapies for follicular thyroid cancer include radioactive iodine therapy and targeted medical therapy.
Medical Therapy
Thyroid Hormone Replacement
- Thyroxine is recommended as a replacement therapy for all patients with follicular thyroid cancer especially for micronodular pulmonary metastases.[1]
Radioactive Iodine Therapy
- Radio active iodine ablation therapy may be used to prevent the recurrence of cancer.
- High doses of radioiodine is also used to treat microscopic bone metastasis
Targeted Therapy
- This type of treatment is done using:[2][3]
- Sorafenib, an Sorafenib is an orally active, multityrosine kinase inhibitor.
- Lenvatinib, an orally active, multitargeted tyrosine kinase inhibitor.[4]
Adult
- Preferred regimen: Lenvatinib 24 mg PO daily until disease progression or unacceptable toxicity.
- Alternative regimen: Sorefenib 400 mg PO q12h until disease progression or unacceptable toxicity.
- Alternative regimen: Larotrectinib 100 mg PO q12h until disease progression or unacceptable toxicity.
- Alternative regimen: Entrectinib 600 mg PO daily until disease progression or unacceptable toxicity.
Radiation Therapy
- External radiation therapy is used for bone pain in bone metastasis.
Other Treatment Options
- Intravenous infusions of bisphosphonate is also used to reduce pain in bone metastasis.
- Corticosteroid therapy is recommended for cerebral edema secondary to brain metastasis.
Treatment Options for Follicular Thyroid Cancer
| Follicular thyroid cnacer treatment | |||||||||||||||||||||||||||||||||||||
| Localized or regional tumor | Metastatic | Recurrent | |||||||||||||||||||||||||||||||||||
| Surgery Total thyroidectomy Lobectomy RAI therapy Thyroid suppression therapy EBRT | Surgery ± postoperative RAI therapy Targeted therapy EBRT Chemotherapy | ||||||||||||||||||||||||||||||||||||
| Iodine sensitive | Iodine resistent | ||||||||||||||||||||||||||||||||||||
| RAI therapy Thyroid suppression therapy | Thyroid suppression therapy Targeted therapy Surgery EBRT | ||||||||||||||||||||||||||||||||||||
| Follicular Thyroid Cancer Treatment Options |
|---|
Reference
- ↑ McHenry, C. R.; Phitayakorn, R. (2011). "Follicular Adenoma and Carcinoma of the Thyroid Gland". The Oncologist. 16 (5): 585–593. doi:10.1634/theoncologist.2010-0405. ISSN 1083-7159.
- ↑ Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL (January 2013). "The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring". J. Clin. Endocrinol. Metab. 98 (1): 31–42. doi:10.1210/jc.2012-2909. PMC 3537108. PMID 23185034.
- ↑ Cabanillas ME, Hu MI, Durand JB, Busaidy NL (2011). "Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer". J Thyroid Res. 2011: 985780. doi:10.4061/2011/985780. PMC 3189619. PMID 22007339.
- ↑ Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (February 2015). "Lenvatinib versus placebo in radioiodine-refractory thyroid cancer". N. Engl. J. Med. 372 (7): 621–30. doi:10.1056/NEJMoa1406470. PMID 25671254.